Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Common Equity (2020 - 2025)

Historic Common Equity for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $207.3 million.

  • Bioventus' Common Equity rose 1093.06% to $207.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $207.3 million, marking a year-over-year increase of 1093.06%. This contributed to the annual value of $185.6 million for FY2024, which is 1606.11% down from last year.
  • Latest data reveals that Bioventus reported Common Equity of $207.3 million as of Q3 2025, which was up 1093.06% from $201.3 million recorded in Q2 2025.
  • In the past 5 years, Bioventus' Common Equity registered a high of $607.7 million during Q4 2021, and its lowest value of $185.5 million during Q1 2025.
  • Over the past 5 years, Bioventus' median Common Equity value was $221.1 million (recorded in 2023), while the average stood at $284.5 million.
  • In the last 5 years, Bioventus' Common Equity surged by 32151.5% in 2021 and then tumbled by 5514.31% in 2023.
  • Over the past 5 years, Bioventus' Common Equity (Quarter) stood at $607.7 million in 2021, then plummeted by 32.16% to $412.2 million in 2022, then tumbled by 46.36% to $221.1 million in 2023, then fell by 16.06% to $185.6 million in 2024, then grew by 11.67% to $207.3 million in 2025.
  • Its Common Equity was $207.3 million in Q3 2025, compared to $201.3 million in Q2 2025 and $185.5 million in Q1 2025.